It was announced today that MSD will construct a new 13,000 square metre facility on a site adjacent to MSD’s existing Carlow plant.
The facility will focus on the production of vaccines and biologics.It is scheduled to commence manufacturing operations in 2022 and will employ an additional 170 staff and 100 contractor staff when operational. The build phase will also see approximately 700 tradespeople employed on site.
The planning application details the construction of a new production building consisting of two production suites – a syringe filling and inspection suite and a vial filling suite – supporting clean utilities as well as an expansion of warehouse at the site.
MSD already employs over 400 people in Carlow and is involved in the manufacture of multiple vaccines and biologics in the MSD product portfolio. The existing site opened in 2008 and was MSD’s first vaccines facility outside of the US.
Speaking this week, Managing Director at MSD Ireland (Human Health), Ger Brennan said, "Over the past 10 years, MSD in Carlow has grown to play a critical role in MSD’s global network of vaccines and biologics facilities – by 2022 this position will have enhanced even further. The continued development of, and investment in, our Irish facilities serves to keep us at the forefront of scientific and medical advancements and helps us achieve our main goal of getting innovative new medicines and vaccines to patients as quickly as possible."